Biopharma and Medtech H1 2023 Round Up: The haves & the have-nots
July 2023
As we cross the mid-year mark, will we see a swing in fortunes? Biopharma share prices were lean in the first quarter of 2023, but the past three months served up some optimism. The promise of treatments for obesity have been a key driver,...
Introduction
Biopharma
Pharma finds a way to gain weight
Stock market strife subsides in second quarter
Venture financing ticks up for biopharma
Biopharma's flotation haul creeps higher
Biopharma buyouts bounce back
Medtech
More, but slower, medtech approvals
Medtech dealmaking grinds almost to a halt
How we help